[ILS-TH-16] Lunch Seminar 16: Changing the treatment paradigm: ranibizumab for myopic CNV
- Apr 03 (Thu)
- 12:15 - 13:15
- Room 23 - Imperial Hotel 3F Fuji
- Novartis Pharma AG
- Retina, Vitreous body
- Chair）Kyoko Ohno-Matsui
- Myopia is an increasingly common eye condition in many countries, particularly in East Asia. In its most severe form, pathological myopia (PM), it is a major cause of visual impairment and blindness worldwide, especially in a younger population. CNV is the most common vision-threatening complication in PM. Ranibizumab provides transformational efficacy with a very low number of injections. It is the first and only anti-VEGF therapy licensed to treat these patients. This symposium discusses clinical evidence supporting the use of ranibizumab in myopic CNV, and introduces the evolving treatment recommendations for optimal management of patients with myopic CNV.